MDT-AP-1301
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 0.24
- os_event
- false
- age_years
- 3
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.254689213
- umap2_2d
- -0.343612041
- umap1_3d
- -1.064707926
- umap2_3d
- -2.481173198
- umap3_3d
- -0.515719112
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.600
- INTERFERON_ALPHA_RESPONSE+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- MYC_TARGETS_V2+0.490
- INTERFERON_GAMMA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.460
- COAGULATION+0.450
- TNFA_SIGNALING_VIA_NFKB+0.450
- IL2_STAT5_SIGNALING+0.410
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.370
- MITOTIC_SPINDLE-0.250
- PROTEIN_SECRETION-0.210
- HEDGEHOG_SIGNALING-0.200
- SPERMATOGENESIS-0.150
- G2M_CHECKPOINT-0.110
- DNA_REPAIR-0.080
- E2F_TARGETS-0.010
- PI3K_AKT_MTOR_SIGNALING+0.000
- UV_RESPONSE_DN+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0821 | Med | Medulloblastoma | 0.927 |
| 2 | MDT-AP-2001 | Med | Medulloblastoma | 0.909 |
| 3 | SRR1335688 | GTEX | — | 0.908 |
| 4 | SRR1407315 | GTEX | — | 0.900 |
| 5 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.893 |
| 6 | SRR1466975 | GTEX | — | 0.887 |
| 7 | SRR13780291 | — | cohortMD2 | 0.885 |
| 8 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.882 |
| 9 | SRR11296840 | — | — | 0.876 |
| 10 | SRR1410783 | GTEX | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |